• news.cision.com/
  • Heliospectra/
  • Sokaogon Medicinal Corporation Deploys Heliospectra Lighting Solutions for Industrial Hemp Cultivation

Sokaogon Medicinal Corporation Deploys Heliospectra Lighting Solutions for Industrial Hemp Cultivation

Report this content

Chippewa Tribal Organization To Achieve Medicinal Grade Crop Quality and Yields with Market-Leading LED Technology

Heliospectra AB (publ) (OTCQB: HLSPY, FIRSTNORTH: HELIO), a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, announces an order from Sokaogon Medicinal Corporation (SMC) of  Mole Lake, Wisconsin. Sokaogon Medicinal Corporation is focused on industrial hemp cultivation for medicinal applications. The order is valued at $232,704 USD (1,948,186 SEK).

Sokaogon Medicinal Corporation is established as an economic corporation of the Sokaogon Chippewa Community. With plans to process and manufacture CBD oil for treatment of epilepsy and other seizure disorders, the facility will deploy Heliospectra E60 series LED lamps with optimized spectra to ensure medicinal grade crop quality and yields.

“Heliospectra offers Sokaogon a robust, durable lighting solution that will withstand the rigors of commercial cultivation,” stated Jimmy Landru, Chairman and CEO, Sokaogon Medicinal Corporation.“The light quality and uniform distribution to the bottom of the plant canopy are essential for Sokaogon to achieve consistent medicinal profiles that deliver predictable and repeatable treatment results for patients.”

The Sokaogon indoor facility includes vegetative and flowering rooms. Designed to drive photosynthesis and optimize growth, the Heliospectra lights will be applied to the complete plant growth and production cycle to ensure whole plant and product purity. 

“The industrial hemp industry demands a reliable solution to standardize plant and product quality. Heliospectra has designed and manufactured proven LED lighting solutions that meet and exceed commercial cultivation performance requirements,” said Ali Ahmadian, CEO, Heliospectra. “We welcome the opportunity to partner with Sokaogon Medicinal Corporation as the organization builds out a holistic cultivation approach and resource-efficient business model.”

Investor Relations:

Ali Ahmadian, CEO of Heliospectra | +46 (0)72 203 6344 | Ali.Ahmadian@heliospectra.com

Redeye is Heliospectra Certified Advisor for Nasdaq First North - www.redeye.se

http://www.heliospectra.com

About Heliospectra

Heliospectra AB (publ) (OTCQB: HLS, FIRST NORTH: HELIO) is the industry’s most proven intelligent lighting technology for greenhouse and controlled plant growth environments. With the vision to make commercial crop production more connected and resource-efficient, growers and commercial producers across six continents use Heliospectra holistic and flexible solutions to consistently increase yields while producing crops that achieve quality appearance, superior nutritional or medicinal value and longer shelf life, harvest after harvest. Founded in 2006 and winner of multiple international awards and recognitions, Heliospectra has raised more than $32 million in capital to date. As a publicly traded company, the majority ownership remains with some of Heliospectra earliest investors Weland Steel, Swedish Industrial Fund and Midroc New Technology. For more information, please visit https://www.heliospectra.com.

Forward-Looking Statements

The statements in this press release constitute forward-looking statements within the meaning of federal securities laws. Such statements are based on our current beliefs and expectations and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control. In addition, such forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Potential risks and uncertainties include, but are not limited to, technical advances in the industry as well as political and economic conditions present within the industry. We do not take any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made.

This information is information that Heliospectra AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14.30 CEST / 8.30 AM EDT on November 21st, 2017.

Tags:

Subscribe

Documents & Links